Insider · CIK 0002025233

Champoux Jennifer

Reports to the SEC for 1 company · BOSTON, MA

sec.gov

Transactions

Companies

Filings

CIK

0002025233

Forms 4 and 5

Insider transactions

21 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-07-15	GLUEMonte Rosa Therapeutics, Inc.M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+4,351 sh	$3.98	+$17.3K	66,722
2026-07-15	GLUEMonte Rosa Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−4,351 sh	$23.38	−$102K	62,371
2026-07-15	GLUEMonte Rosa Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−4,351 sh	—	—	26,947
2026-06-23	GLUEMonte Rosa Therapeutics, Inc.M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+2,175 sh	$3.98	+$8,656.5	64,546
2026-06-23	GLUEMonte Rosa Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−2,175 sh	$20.00	−$43.5K	62,371
2026-06-23	GLUEMonte Rosa Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−2,175 sh	—	—	31,298
2026-06-17	GLUEMonte Rosa Therapeutics, Inc.M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+2,176 sh	$3.98	+$8,660.48	64,547
2026-06-17	GLUEMonte Rosa Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−2,176 sh	$19.00	−$41.3K	62,371
2026-06-17	GLUEMonte Rosa Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−2,176 sh	—	—	33,473
2026-05-27	GLUEMonte Rosa Therapeutics, Inc.M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+2,175 sh	$3.98	+$8,656.5	64,546
2026-05-27	GLUEMonte Rosa Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−2,175 sh	$20.00	−$43.5K	62,371
2026-05-27	GLUEMonte Rosa Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−2,175 sh	—	—	35,649
2026-05-22	GLUEMonte Rosa Therapeutics, Inc.M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+2,176 sh	$3.98	+$8,660.48	64,547
2026-05-22	GLUEMonte Rosa Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−2,176 sh	$19.00	−$41.3K	62,371
2026-05-22	GLUEMonte Rosa Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−2,176 sh	—	—	37,824
2026-01-05	GLUEMonte Rosa Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−2,629 sh	$15.17	−$39.9K	62,371
2026-01-02	GLUEMonte Rosa Therapeutics, Inc.A Award	Chief Operating Officer	AAward	+35K sh	—	—	65,000
2026-01-02	GLUEMonte Rosa Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Operating Officer	AAward	+158K sh	—	—	158,000
2025-01-02	GLUEMonte Rosa Therapeutics, Inc.A Award	Chief Operating Officer	AAward	+30K sh	—	—	30,000
2025-01-02	GLUEMonte Rosa Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Operating Officer	AAward	+135K sh	—	—	135,000
2024-06-03	GLUEMonte Rosa Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Operating Officer	AAward	+40K sh	—	—	40,000

Recent filings

Accepted (ET)
Jul 164
Champoux Jennifer0001193125-26-306110
SEC(opens sec.gov)
Jun 254
Champoux Jennifer0001193125-26-282735
SEC(opens sec.gov)
Jun 184
Champoux Jennifer0001193125-26-275806
SEC(opens sec.gov)
May 284
Champoux Jennifer0001193125-26-245728
SEC(opens sec.gov)
May 264
Champoux Jennifer0001193125-26-239240
SEC(opens sec.gov)
Jan 54
Champoux Jennifer0001193125-26-002401
SEC(opens sec.gov)
Jan 64
Champoux Jennifer0000950170-25-002101
SEC(opens sec.gov)

Companies

Monte Rosa Therapeutics, Inc.Chief Operating OfficerGLUE

Address

MONTE ROSA THERAPEUTICS, INC. 321 HARRISON AVENUE, SUITE 900

BOSTON, MA, 02118